Pseudogene RACGAP1P activates RACGAP1/Rho/ERK signalling axis as a competing endogenous RNA to promote hepatocellular carcinoma early recurrence

被引:36
|
作者
Wang, Meng-Yao [1 ]
Chen, Dong-Ping [1 ]
Qi, Bin [1 ]
Li, Ming-Yi [1 ]
Zhu, Yan-Yi [1 ]
Yin, Wen-Jing [1 ]
He, Lu [1 ]
Yu, Yi [1 ]
Li, Zhou-Yu [1 ]
Lin, Ling [1 ]
Yang, Fang [1 ]
Lin, Zhi-Rui [2 ]
Liu, Jin-Quan [1 ]
机构
[1] Guangzhou Med Univ, Affiliated Canc Hosp & Inst, Dept Radiat Oncol, Guangzhou 510245, Guangdong, Peoples R China
[2] Sun Yat Sen Univ, Canc Ctr, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou 510245, Guangdong, Peoples R China
基金
中国国家自然科学基金;
关键词
CERNA HYPOTHESIS; EXPRESSION; GENE; IDENTIFICATION; PROTEIN; CANCER; RAC;
D O I
10.1038/s41419-019-1666-2
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Accumulating evidence has indicated crucial roles for pseudogenes in human cancers. However, the roles played by pseudogenes in the pathogenesis of HCC, particularly HCC early recurrence, still incompletely elucidated. Herein, we identify a novel early recurrence related pseudogene RACGAP1P which was significantly upregulated in HCC and was associated with larger tumour size, advanced clinical stage, abnormal AFP level and shorter survival time. In vitro and in vivo experiments have shown that RACGAP1P is a prerequisite for the development of malignant characteristics of HCC cells, including cell growth and migration. Mechanistic investigations indicated that RACGAP1P elicits its oncogenic activity as a ceRNA to sequestrate miR-15-5p from its endogenous target RACGAP1, thereby leading to the upregulation of RACGAP1 and the activation of RhoA/ERK signalling. These results may provide new insights into the functional crosstalk of the pseudogene/miRNA/parent-gene genetic network during HCC early relapse and may contribute to improving the clinical intervention for this subset of HCC patients.
引用
收藏
页数:12
相关论文
共 7 条
  • [1] HIF-1α and RACGAP1 promote the progression of hepatocellular carcinoma in a mutually regulatory way
    Wu, Xianjian
    Xu, Zuoming
    Li, Wenchuan
    Lu, Yuan
    Pu, Jian
    MOLECULAR MEDICINE REPORTS, 2023, 28 (05)
  • [2] LINC00346 Acts as a Competing Endogenous RNA Regulating Development of Hepatocellular Carcinoma via Modulating CDK1/CCNB1 Axis
    Jin, Jinglan
    Xu, Hongqin
    Li, Wanyu
    Xu, Xiaotong
    Liu, Huan
    Wei, Feng
    FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY, 2020, 8
  • [3] Long noncoding RNA AFAP1-AS1 acts as a competing endogenous RNA of miR-423-5p to facilitate nasopharyngeal carcinoma metastasis through regulating the Rho/Rac pathway
    Lian, Yu
    Xiong, Fang
    Yang, Liting
    Bo, Hao
    Gong, Zhaojian
    Wang, Yumin
    Wei, Fang
    Tang, Yanyan
    Li, Xiayu
    Liao, Qianjin
    Wang, Hui
    Zhou, Ming
    Xiang, Bo
    Wu, Xu
    Li, Yong
    Li, Xiaoling
    Chen, Xiang
    Li, Guiyuan
    Guo, Can
    Zeng, Zhaoyang
    Xiong, Wei
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2018, 37
  • [4] Long noncoding RNA LINC00518 acts as a competing endogenous RNA to promote the metastasis of malignant melanoma via miR-204-5p/AP1S2 axis
    Luan, Wenkang
    Ding, Yuting
    Ma, Shaojun
    Ruan, Hongru
    Wang, Jinlong
    Lu, Feng
    CELL DEATH & DISEASE, 2019, 10 (11)
  • [5] Long noncoding RNA PSMA3-AS1 functions as a competing endogenous RNA to promote gastric cancer progression by regulating the miR-329-3p/ALDOA axis
    Kan, Liang
    Yang, Meiqi
    Zhang, Huijing
    BIOLOGY DIRECT, 2023, 18 (01)
  • [6] Circular RNA hsa_circRNA_103809 promoted hepatocellular carcinoma development by regulating miR-377-3p/FGFR1/ERK axis
    Zhan, Wei
    Liao, Xin
    Chen, Zhongsheng
    Li, Lianghe
    Tian, Tian
    Yu, Lei
    Wang, Wei
    Hu, Qiyan
    JOURNAL OF CELLULAR PHYSIOLOGY, 2020, 235 (02) : 1733 - 1745
  • [7] Identification of hsa_circ_0002024 as a prognostic competing endogenous RNA (ceRNA) through the hsa_miR_129-5p/Anti-Silencing Function 1B Histone Chaperone (ASF1B) axis in renal cell carcinoma
    Chen, Zhe
    Ou, Dehua
    Huang, Zhuangkai
    Shen, Peilin
    BIOENGINEERED, 2021, 12 (01) : 6579 - 6593